WHO Expert Committee on Specifications for Pharmaceutical Preparations - WHO Technical Report Series, No. 834 - Thirty-third Report
(1993; 36 pages) View the PDF document
Table of Contents
View the documentWHO Expert Committee on Specifications for Pharmaceutical Preparations
View the document1. Introduction
Close this folder2. The international pharmacopoeia and related activities
View the document2.1. Quality specifications for drug substances and dosage forms
View the document2.2. Dissolution test for solid oral dosage forms: paddle method
View the document2.3. Therapeutic equivalence of multisource products
View the document2.4. International nonproprietary names for pharmaceutical substances
Open this folder and view contents3. International Chemical Reference Substances and International Infrared Reference Spectra
View the document4. Quality control methods for medicinal plant materials
View the document5. The WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce
Open this folder and view contents6. Good manufacturing practices for pharmaceutical products
View the document7. Development of globally acceptable standards for excipients
Open this folder and view contents8. Stability of dosage forms
View the document9. Simple test methodology
View the document10. Quality assurance in pharmaceutical supply systems
Open this folder and view contents11. Pharmaceutical production in developing countries
View the document12. Training
View the documentAcknowledgements
View the documentReferences
View the documentAnnex 1 - List of available International Chemical Reference Substances1
View the documentAnnex 2 - List of available International Infrared Reference Spectra
Open this folder and view contentsAnnex 3 - Good manufacturing practices for biological products1
View the documentBack Cover
 

2.4. International nonproprietary names for pharmaceutical substances

The Committee was informed of the current activities of the programme on international nonproprietary names (INNs) for pharmaceutical substances. It agreed that there was a case for increased protection of INNs, as pointed out in the fifth report of the WHO Expert Committee on the Use of Essential Drugs (1). The difficulty of establishing appropriate names for the wide range of compounds produced by biotechnology was recognized. It was agreed that wide consultation with experts from the relevant disciplines would be advisable to establish policy in this field.

The Committee noted that guidelines for the drawing of graphic formulae for pharmaceutical substances were in preparation, an area where global harmonization is needed.

 

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: October 7, 2014